MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2025 International Congress

    CSF Cadaverine and Other Polyamines as Biomarkers of Parkinson’s Disease: A PPMI Metabolomics Analysis

    N. Xia, R. Maciuca, J. Suh, J. Kluss, S. Davis, R. Bakshi, G. Crotty, A. Ascherio, E. Macklin, S. Huntwork-Rodriguez, M. Schwarzschild (Charlestown, USA)

    Objective: To identify novel biomarkers of Parkinson’s disease (PD) in Parkinson's Progression Markers Initiative (PPMI) cerebrospinal fluid (CSF) samples. Background: Altered polyamine levels in plasma…
  • 2025 International Congress

    Immune cell changes in early Dementia with Lewy Bodies

    T. Yacoubian, H. Qin, A. Amara, N. Stover, L. Ruffrage, M. Dean, Y. Zhang, R. Kennedy, D. Geldmacher, A. Gerstenecker, D. Standaert, E. Benveniste (AURORA, USA)

    Objective: To examine if immune cell changes are present in early stages of Dementia with Lewy Bodies (DLB). Background: Evidence for inflammation in synucleinopathies has…
  • 2025 International Congress

    Reliability and Validity of In-home Tele-Neuropsychological Testing in Patients with Parkinson’s Disease: A Randomized Trial

    S. Sperling, J. Dong, B. Lapin, Y. Li (Cleveland, USA)

    Objective: To assess the reliability and diagnostic validity of in-home tele-neuropsychological testing (in-home tele-npt) in individuals with Parkinson’s disease (PD). Background: Neuropsychological testing is inaccessible…
  • 2025 International Congress

    Baseline cerebrospinal levels of p-tau and amyloid beta and striatal dopamine transporter binding predict mild cognitive impairment and dementia diagnosis in Parkinson’s disease

    L. Collins-Praino, A. Mcnamara, I. Baetu (Adelaide, Australia)

    Objective: To assess whether baseline measurements of neuroimaging and biofluid-based biomarkers predict diagnosis of mild cognitive impairment (MCI) and dementia at 5-year follow-up in early…
  • 2025 International Congress

    Atypical Psychosis in Parkinson Disease: A Retrospective Study on 24-Hour Continuous Subcutaneous Infusion Foslevodopa/Foscarbidopa Therapy

    K. Ikenaka, K. Kakuda, Y. Kimura, H. Mochizuki (Suita, Japan)

    Objective: This study aims to identify clinical predictors of continuous subcutaneous infusion (CSCI)-induced psychosis to understand its potential mechanisms and evaluate predictive measures for its…
  • 2025 International Congress

    Demographic Features, QTc Interval and Psychosis in Military Veterans with Parkinson’s disease (PD)

    A. Sarwar, P. Bigner (Houston, USA)

    Objective: To compare certain key demographic features and QTc intervals in groups of PD military Veterans with and without psychosis. Background: Psychosis is a disabling…
  • 2025 International Congress

    The relationship between synuclein-related biomarkers and people with upper-respiratory causes of hyposmia or persistent hyposmia

    E. Brown, T. Tropea, A. Siderowf, L. Heathers, T. Foroud, C. Gochanour, C. Caspell-Garcia, M. Marshall, R. Kurth, T. Simuni, K. Marek, C. Tanner (San Francisco, USA)

    Objective: To determine how smell-testing can enrich screening for individuals with biomarkers related to neuronal alpha-synucleinopathy-related neurodegeneration (NSD). Background: Loss of sense of smell is the…
  • 2025 International Congress

    Knowledge, Perception and Access to Care for Parkinson’s Disease in Two Selected Local Government Areas in Lagos State, Southwestern Nigeria.

    O. Ibode, A. Ogunyemi, O. Ojo, R. Walker, N. Okubadejo (Lagos, Nigeria)

    Objective: We aimed to study the knowledge and perception of Parkinson’s disease (PD) and awareness of available care options for PD diagnosis in our population.…
  • 2025 International Congress

    Real-life experience with continuous subcutaneous foslevodopa/foscarbidopa infusion in advanced stage of Parkinson’s disease at Villa Margherita

    G. Nordera, N. Bonetto, F. Perini (Vicenza, Italy)

    Objective: We present the results of our case series with continuous subcutaneous infusion (CSCI) produodopa in 2024, focusing on tolerability and efficacy, in line with…
  • 2025 International Congress

    Nasal septum deviation correlates with asymmetry in Parkinson’s disease

    J. Wang, J. Wang, F. Liu, C. Zuo, Y. Sun, J. Wu (Shanghai, China)

    Objective: To assesse whether asymmetry in the nasal cavity is related to dopaminergic dysfunction asymmetry in PD patients Background: Asymmetry in motor dysfunction and associated dopaminergic…
  • « Previous Page
  • 1
  • …
  • 63
  • 64
  • 65
  • 66
  • 67
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley